| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Kaji-ichigoside F1 acts on multiple targets. It exhibits inhibitory activity on the NF-κB pathway, reducing the expression of pro-inflammatory mediators. It also activates the Nrf2-mediated antioxidant response, upregulating heme oxygenase-1 (HO-1) and glutathione S-transferase. In addition, it has been reported to inhibit the activation of hepatic stellate cells, offering hepatoprotection.
|
|---|---|
| ln Vitro |
In vitro, Kaji-ichigoside F1 inhibits LPS-induced NO production in RAW 264.7 macrophages with an IC50 of 8.5 µM. It also suppresses TNF-α, IL-1β, and IL-6 secretion at 5-20 µM. The compound shows moderate cytotoxicity against human HepG2 liver cancer cells (IC50 ~ 25 µM) and MCF-7 breast cancer cells (IC50 ~ 30 µM) after 48 hours. It demonstrates significant DPPH radical scavenging activity (IC50 ~ 12 µM).
|
| ln Vivo |
In vivo, Kaji-ichigoside F1 has hepatoprotective effects in animal models. In a mouse model of CCl₄-induced acute liver injury, oral administration of Kaji-ichigoside F1 (20-100 mg/kg) significantly reduced serum ALT and AST levels and improved liver histology. In a rat model of carrageenan-induced paw edema, the compound reduced swelling at doses of 10-50 mg/kg (i.p.). In a xenograft mouse model, it showed modest tumor growth inhibition.
|
| Enzyme Assay |
The in vitro NF-κB inhibition assay involves culturing RAW 264.7 macrophages in 24-well plates. Cells are pre-treated with various concentrations of Kaji-ichigoside F1 (1-50 µM) for 2 hours, then stimulated with LPS (1 µg/mL) for an additional 6 hours. The cells are harvested, and nuclear extracts are prepared. NF-κB p65 DNA-binding activity is measured using an ELISA-based TransAM NF-κB assay kit.
|
| Cell Assay |
For in vitro cell-based assays, HepG2 or RAW 264.7 cells are seeded in 96-well plates at 1 × 10⁴ cells/well. The compound is dissolved in DMSO and diluted to final concentrations of 1, 5, 10, 20, 50, and 100 µM. After treatment for 24-48 hours, cell viability is determined by MTT assay. For anti-inflammatory assays, supernatants are collected for cytokine measurement by ELISA. Intracellular ROS is measured using DCFH-DA.
|
| Animal Protocol |
For in vivo hepatoprotection studies, male ICR mice (25-30 g) are divided into groups (n=10). Kaji-ichigoside F1 is dissolved in 0.5% CMC-Na and administered orally at doses of 20, 40, or 80 mg/kg daily for 7 days. On day 7, acute liver injury is induced by a single intraperitoneal injection of 0.5% CCl₄ in olive oil (10 mL/kg). After 24 hours, blood and liver samples are collected for biochemical and histopathological analyses.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Kaji-ichigoside F1 are very limited. In one rat study, oral administration (50 mg/kg) resulted in low bioavailability (<5%) due to extensive metabolism by intestinal flora and poor absorption. The compound is hydrophilic and likely excreted via the biliary route. Plasma protein binding has not been determined. No detailed PK parameters such as half-life or volume of distribution are available.
|
| Toxicity/Toxicokinetics |
Kaji-ichigoside F1 has low acute toxicity. The oral LD50 in mice is estimated to be >1000 mg/kg. In subchronic studies, doses up to 200 mg/kg/day for 14 days showed no significant adverse effects on body weight, organ weights, or serum biochemistry. No cytotoxicity was observed in normal cells (e.g., hepatocytes) at concentrations below 50 µM. The compound is not mutagenic in the Ames test.
|
| References | |
| Additional Infomation |
It has been reported that Rosa laevigata, Rubus ellipticus var. contain kaji-ichigoside F1, obcordatus, and other organisms with available data.
Kaji-ichigoside F1 is an off-white to light yellow amorphous powder. It is soluble in methanol, ethanol, and DMSO but poorly soluble in water. It is a component of traditional herbal medicines used for liver protection. The compound is a research tool for studying the pharmacological effects of triterpenoid saponins. Its mechanism involves multiple pathways, making it a promising lead for the development of hepatoprotective agents. |
| Molecular Formula |
C36H58O10
|
|---|---|
| Molecular Weight |
650.8397
|
| Exact Mass |
650.403
|
| CAS # |
95298-47-8
|
| PubChem CID |
14019178
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
741.5±60.0 °C at 760 mmHg
|
| Flash Point |
223.6±26.4 °C
|
| Vapour Pressure |
0.0±5.6 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
5.33
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
46
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@H](C5(C)C)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O
|
| InChi Key |
MLKQAGPAYHTNQQ-FUZXVMJXSA-N
|
| InChi Code |
InChI=1S/C36H58O10/c1-18-10-13-36(30(43)46-29-26(41)25(40)24(39)21(17-37)45-29)15-14-33(5)19(27(36)35(18,7)44)8-9-23-32(4)16-20(38)28(42)31(2,3)22(32)11-12-34(23,33)6/h8,18,20-29,37-42,44H,9-17H2,1-7H3/t18-,20-,21-,22+,23-,24-,25+,26-,27-,28-,29+,32+,33-,34-,35-,36+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,11R,12aR,14bS)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5365 mL | 7.6824 mL | 15.3648 mL | |
| 5 mM | 0.3073 mL | 1.5365 mL | 3.0730 mL | |
| 10 mM | 0.1536 mL | 0.7682 mL | 1.5365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
